Drug Profile
Research programme: monoclonal antibodies - Regeneron
Alternative Names: VelocImmune® research programme - RegeneronLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Eye disorders; Immunological disorders; Inflammation; Metabolic disorders; Musculoskeletal disorders; Pain
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)